Cox proportional hazards model showed that SGLT2 inhibitors use (compared with DPP4 inhibitors use) was associated with a 23% reduction in the risk of prostate cancer (SGLT2 inhibitors use = 467.4 versus DPP4 inhibitors use = 492.75 per 100,000 person-years; hazard ratio [HR] = 0.77, 95% CI = 0.61 to 0.99, p = 0.03) during a median follow-up of 1.33 years (Figure 3B). The gene discussed is SLC5A2; the disease is Familial prostate cancer.